This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
SYMPLICITY HTN-3 was a randomized, parallel-design clinical trial evaluating renal denervation using the Symplicity Catheter System in patients with uncontrolled hypertension.
| Feature | SYMPLICITY HTN-3 |
|---|---|
| Condition | Uncontrolled Hypertension |
| Design | Randomized, parallel, single-masked |
| Primary purpose | Treatment |
| Phase | NA |
| Sponsor | Medtronic Vascular |
| Intervention | Renal denervation (Symplicity Catheter System) |
| Comparator | Renal angiogram (diagnostic_test) |
2. Clinical Question
Population
Patients with uncontrolled hypertension.
Intervention
Renal denervation using the Symplicity Catheter System.
Comparator
Renal angiogram as the comparator intervention.
Primary question
Does renal denervation affect change in office systolic blood pressure from baseline to 6 months post-randomization?
3. Trial Design
Randomized
Parallel assignment
Single
2 study arms
4. Endpoints
| Endpoint | Definition | Time Frame |
|---|---|---|
| Change in Office Systolic Blood Pressure | Primary Effectiveness Outcome Measure | Baseline to 6 months post-randomization |
5. Planned Analysis
The ClinicalTrials.gov record identifies the primary effectiveness endpoint as change in office systolic blood pressure from baseline to 6 months post-randomization. No formal statistical analyses were posted to ClinicalTrials.gov.
Analysis approach for this endpoint
A continuous change-from-baseline endpoint is typically evaluated by comparing mean change between randomized groups. Common approaches include analysis of covariance (ANCOVA), which adjusts the follow-up measurement for baseline blood pressure and estimates the treatment-group difference while accounting for baseline imbalance.
The interpretation focuses on the estimated difference between groups, its confidence interval, and the uncertainty associated with the estimate.
6. Statistical Methodology
Randomization
Randomization creates treatment groups that are expected, on average, to be comparable with respect to measured and unmeasured baseline characteristics. This allows differences observed after treatment assignment to be interpreted within the randomized comparison framework.
Continuous outcomes and treatment effects
For a blood pressure change endpoint, the treatment effect is usually expressed as the difference in mean change between groups. Confidence intervals describe the precision of that estimated difference.
Analysis of covariance
ANCOVA is frequently used for continuous clinical trial outcomes because baseline adjustment can improve precision compared with analyzing change scores alone.
7. Statistical Methods Explained
Why is change from baseline used?
Change from baseline measures how much the outcome shifts after randomization. It focuses the comparison on improvement or worsening over the study period.
Why adjust for baseline values?
Baseline adjustment can reduce unexplained variability because participants begin with different blood pressure measurements.
What does a confidence interval show?
A confidence interval describes uncertainty around an estimated treatment difference. It does not describe the range of responses experienced by individual patients.
Why does randomization matter?
Randomization protects the validity of comparisons by reducing systematic differences between assigned groups.
Why are p-values not enough?
A p-value addresses compatibility with a statistical model under a null hypothesis. It does not describe the magnitude or clinical importance of an effect.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or endpoint results.
- The registry does not report baseline characteristics, subgroup analyses, safety results, or detailed analysis populations.
- Without posted estimates and uncertainty measures, treatment effects cannot be quantified from the registry record alone.
- Single primary endpoint trials still require careful interpretation of endpoint definition, missing data handling, and analysis assumptions.
9. Why This Trial Matters Statistically
| Concept | How it appears in SYMPLICITY HTN-3 |
|---|---|
| Randomization | Randomized parallel trial design |
| Continuous endpoint | Change in office systolic blood pressure |
| Baseline adjustment | Relevant consideration for blood pressure analysis |
| Effect estimation | Difference between randomized groups |
| Precision | Confidence intervals around treatment estimates |